Robert W. Baird Increases Amedisys (AMED) Price Target to $120.00

Amedisys (NASDAQ:AMED) had its price target upped by equities research analysts at Robert W. Baird from $105.00 to $120.00 in a research note issued to investors on Thursday, Stock Target Advisor reports. The brokerage currently has a “neutral” rating on the health services provider’s stock. Robert W. Baird’s price target would suggest a potential upside of 9.81% from the stock’s previous close.

Other equities research analysts also recently issued reports about the stock. SunTrust Banks increased their price objective on shares of Amedisys to $130.00 and gave the stock a “buy” rating in a research note on Thursday. Bank of America set a $139.00 price objective on shares of Amedisys and gave the stock a “buy” rating in a research note on Tuesday, September 18th. BidaskClub downgraded shares of Amedisys from a “strong-buy” rating to a “buy” rating in a research note on Monday, June 18th. Cantor Fitzgerald increased their price objective on shares of Amedisys from $117.00 to $125.00 and gave the stock a “neutral” rating in a research note on Thursday. Finally, Canaccord Genuity initiated coverage on shares of Amedisys in a research note on Thursday, September 13th. They issued a “neutral” rating and a $117.00 price target on the stock. Five equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $95.38.

Shares of Amedisys stock opened at $109.28 on Thursday. The stock has a market cap of $3.98 billion, a price-to-earnings ratio of 51.86, a PEG ratio of 1.89 and a beta of 1.00. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.21 and a current ratio of 1.21. Amedisys has a 12-month low of $45.60 and a 12-month high of $127.38.

Amedisys (NASDAQ:AMED) last announced its quarterly earnings data on Tuesday, July 31st. The health services provider reported $1.00 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.78 by $0.22. The firm had revenue of $411.60 million for the quarter, compared to the consensus estimate of $403.62 million. Amedisys had a net margin of 4.46% and a return on equity of 20.11%. During the same period in the prior year, the company posted $0.62 earnings per share. On average, analysts predict that Amedisys will post 3.41 EPS for the current fiscal year.

In other news, insider David B. Pearce sold 398 shares of the firm’s stock in a transaction that occurred on Tuesday, September 25th. The shares were sold at an average price of $121.71, for a total value of $48,440.58. Following the sale, the insider now directly owns 11,818 shares in the company, valued at approximately $1,438,368.78. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 2.60% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the company. Glenmede Trust Co. NA boosted its stake in shares of Amedisys by 4.3% in the 2nd quarter. Glenmede Trust Co. NA now owns 71,559 shares of the health services provider’s stock valued at $6,116,000 after purchasing an additional 2,959 shares in the last quarter. Moneta Group Investment Advisors LLC acquired a new stake in Amedisys during the 2nd quarter worth approximately $181,000. Algert Global LLC acquired a new stake in Amedisys during the 2nd quarter worth approximately $1,208,000. Piedmont Investment Advisors LLC boosted its position in Amedisys by 9.3% during the 2nd quarter. Piedmont Investment Advisors LLC now owns 6,668 shares of the health services provider’s stock worth $570,000 after buying an additional 567 shares during the period. Finally, Cubist Systematic Strategies LLC boosted its position in Amedisys by 1,086.0% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 2,372 shares of the health services provider’s stock worth $203,000 after buying an additional 2,172 shares during the period. Institutional investors own 93.31% of the company’s stock.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.

See Also: Leveraged Buyout (LBO)

Stock Target Advisor

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply